Hamid Irannejad

Prof. Hamid Irannejad

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2010 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
HIHamid Irannejad
Hamid Irannejad
MAMohsen Amini
Mohsen Amini
FKFariba Khodagholi
Fariba Khodagholi
NANiloufar Ansari
Niloufar Ansari
STSolaleh Khoramian Tusi
Solaleh Khoramian Tusi
ASAbbas Shafiee
Abbas Shafiee

1 August 2018 in Bioorganic Chemistry
Verified
Journal Article
Closed access
LDLeila Dehestani
Leila Dehestani
NANematollah Ahangar
Nematollah Ahangar
SHSeyedeh Mahdieh Hashemi
Seyedeh Mahdieh Hashemi
HIHamid Irannejad
Hamid Irannejad
PMPatrick Honarchian Masihi
Patrick Honarchian Masihi
SESaeed Emami
Saeed Emami

1 October 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SESaeed Emami
Saeed Emami
EGEbrahim Ghafouri
Ebrahim Ghafouri
MFMohammad Ali Faramarzi
Mohammad Ali Faramarzi
NSNasrin Samadi
Nasrin Samadi
HIHamid Irannejad
Hamid Irannejad
AFAlireza Foroumadi
Alireza Foroumadi

29 September 2021 in Cell Cycle
Verified
Journal Article
Closed access
Mehdi ValipourMehdi Valipour
Mehdi Valipour
AZAfshin Zarghi
Afshin Zarghi
MEMohammad Ali Ebrahimzadeh
Mohammad Ali Ebrahimzadeh
HIHamid Irannejad
Hamid Irannejad
Multifunctional nature of phytochemicals and their chemical diversity has attracted attention to develop leads originated from nature to fight COVID-19. Pharmacological activities of chelerythrine and its congeners have been studied and reported in the literature. This compound simultaneously has two key therapeutic effects for the treatment of COVID-19, antiviral and anti-inflammatory activities. Chelerythrine can prevent hyper-inflammatory immune response through regulating critical signaling pathways involved in SARS-CoV-2 infection, such as alteration in Nrf2, NF-κB, and p38 MAPK activities. In addition, chelerythrine has a strong protein kinase C-α/-β inhibitory activity suitable for cerebral vasospasm prevention and eryptosis reduction, as well as beneficial effects in suppressing pulmonary inflammation and fibrosis. In terms of antiviral activity, chelerythrine can fight with SARS-CoV-2 through various mechanisms, such as direct-acting mechanism, viral RNA-intercalation, and regulation of host-based antiviral targets. Although chelerythrine is toxic in vitro, the in vivo toxicity is significantly reduced due to its structural conversion to alkanolamine. Its multifunctional action makes chelerythrine a prominent compound for the treatment of COVID-19. Considering precautions related to the toxicity at higher doses, it is expected that this compound is useful in combination with proper antivirals to reduce the severity of COVID-19 symptoms.

1 January 2014 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
HIHamid Irannejad
Hamid Irannejad
AKAbbas Kebriaieezadeh
Abbas Kebriaieezadeh
AZAfshin Zarghi
Afshin Zarghi
FMFarhad Montazer-Sadegh
Farhad Montazer-Sadegh
ASAbbas Shafiee
Abbas Shafiee
MAMohsen Amini
Mohsen Amini